CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number : 040210

Trade Name : HYDROCODONE BITRATRATE AND ACETAMINOPHEN TABLETS USP, 10MG/500MG

Generic Name: Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/500mg

Sponsor : Peachtree Pharmaceuticals

Approval Date: August 13, 1997

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION 040210

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tenative Approval Letter				
Approvable Letter				
Final Printed Labeling	X			
Medical Review(s)				
Chemistry Review(s)	X			
EA/FONSI				
Pharmacology Review(s)				
Statistical Review(s)				
Microbiology Review(s)				
Clinical Pharmacology Biopharmaceutics Review(s)				
Bioequivalence Review(s)	X			
Administrative Document(s)				
Correspondence				

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number 040210

APPROVAL LETTER

ANDA 40-210

AUG 13 1997

Peachtree Pharmaceuticals
Attention: Diane F. Vandeputte, Ph.D.
1950 Lake Park Drive
Smyrna, GA 30080

Dear Madam:

This is in reference to your abbreviated new drug application dated September 13, 1996, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/500 mg.

Reference is also made to your amendments dated November 15, 1996; and April 4, May 19, and July 24, 1997.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10 mg/500 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Lortab® 10/500 of DM Graham Laboratories Inc.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-240). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-240) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

/S/ 8/13/97

Douglas L. Sporn
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 040210

FINAL PRINTED LABELING

Copy 2

AUG 13 1997

PHARMACIST: Dispense in a tight, light-resistant container with a child-resistant closure.

Store at controlled room temperature, 15°-30°C (59°-86°F).

Lot No.:
Exp. Date:

Manufactured for
Peachtree Pharmaceuticals
Smyrna, GA 30080
by D.M. Graham Laboratories, Inc.
Hobart, NY 13788

NDC 62793-710-01 **100 TABLETS**

HYDROCODONE* BITARTRATE AND ACETAMINOPHEN TABLETS, USP
10 mg/500 mg

***Warning: May be habit forming.**

Each tablet contains:
Hydrocodone* Bitartrate . . . . . 10 mg
*Warning: May be habit forming.
Acetaminophen . . . . . 500 mg

CAUTION: Federal law prohibits dispensing without prescription.

USUAL DOSAGE: See package insert for complete dosage recommendations.

N 3 62793-710-01 7

Rev. 7/97
7G14007A

AUG 13 1997

PHARMACIST: Dispense in tight, light-resistant container with a child-resistant closure.

Store at controlled room temperature, 15°-30°C (59°-86°F).

Lot No.:
Exp. Date:

Manufactured for
Peachtree Pharmaceuticals
Smyrna, GA 30080
by D.M. Graham Laboratories, Inc.
Hobart, NY 13788

NDC 62793-710-50 **500 TABLETS**

HYDROCODONE* BITARTRATE AND ACETAMINOPHEN TABLETS, USP
10 mg/500 mg

***Warning: May be habit forming.**

Each tablet contains:
Hydrocodone* Bitartrate . . . . . 10 mg
*WARNING: May be habit forming.
Acetaminophen . . . . . 500 mg

CAUTION: Federal law prohibits dispensing without prescription.

USUAL DOSAGE: See package insert for complete dosage recommendations.

N 3 62793-710-50 5

Rev. 7/97
7G14017A

:bular necrosis, hypoglycemic coma and thrombocytopenia may also occur.

arly symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and boratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 grams, or fatalities with less than 15 grams.

reatment: A single or multiple overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, and consultation ith a regional poison control center is recommended.

mediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced echanically, or with syrup of ipecac, if the patient is alert (adequate pharyngeal and laryngeal reflexes). Oral activated charcoal (1 g/kg) hould follow gastric emptying. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic ight be included with alternate doses as required. Hypotension is usually hypovolemic and should respond to fluids. Vasopressors and her supportive measures should be employed as indicated. A cuffed endo-tracheal tube should be inserted before gastric lavage of the nconscious patient and, when necessary, to provide assisted respiration.

eticulous attention should be given to maintaining adequate pulmonary ventilation. In severe cases of intoxication, peritoneal dialysis, or eferably hemodialysis may be considered. If hypoprothrombinemia occurs due to acetaminophen overdose, vitamin K should be adminis- red intravenously.

aloxone, a narcotic antagonist, can reverse respiratory depression and coma associated with opioid overdose. Naloxone hydrochloride 0.4 mg 2 mg is given parenterally. Since the duration of action of hydrocodone may exceed that of the naloxone, the patient should be kept under ntinuous surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic tagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression.

the dose of acetaminophen may have exceeded 140 mg/kg, acetylcysteine should be administered as early as possible. Serum acetaminophen vels should be obtained, since levels four or more hours following ingestion help predict acetaminophen toxicity. Do not await acetaminophen say results before initiating treatment. Hepatic enzymes should be obtained initially, and repeated at 24-hour intervals.

ethemoglobinemia over 30% should be treated with methylene blue by slow intravenous administration.

e toxic dose for adults for acetaminophen is 10 g.

DOSAGE AND ADMINISTRATION

osage should be adjusted according to severity of pain and response of the patient. However, it should be kept in mind that tolerance to drocodone can develop with continued use and that the incidence of untoward effects is dose related.

e usual adult dosage is one tablet every four to six hours as needed for pain. The total daily dosage should not exceed 6 tablets.

HOW SUPPLIED

drocodone Bitartrate and Acetaminophen Tablets, USP, 10 mg/500 mg, contain hydrocodone bitartrate 10 mg (Warning: May be habit rming) and acetaminophen 500 mg. They are supplied as unscored, white, capsule-shaped tablets, debossed "PTP/710," in containers of 0 tablets NDC 62793-710-01 and in containers of 500 tablets NDC 62793-710-50.

torage: Store at controlled room temperature, 15°-30°C (59°-86°F).

spense in a tight, light-resistant container with a child-resistant closure.

aution: Federal law prohibits dispensing without prescription.

Schedule CIII Narcotic.

Manufactured for:
Peachtree Pharmaceuticals
Smyrna, Georgia 30080

Manufactured by:
D.M. GRAHAM LABORATORIES, INC.
Hobart, New York 13788

vised 4/97
N 7H14008

37100497

HYDROCODONE* BITARTRATE AND ACETAMINOPHEN TABLETS, USP 10 mg/500 mg

CIII

***Warning: May be habit forming.**

DESCRIPTION

Hydrocodone bitartrate and acetaminophen is supplied in tablet form for oral administration.

Hydrocodone bitartrate is an opioid analgesic and antitussive and occurs as fine, white crystals or as a crystalline powder. It is affected by light. The chemical name is 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). It has the following structural formula:



$C_{18}H_{21}NO_3 \bullet C_4H_6O_6 \bullet 2^1/_2H_2O$ MW = 494.50

Acetaminophen, 4'-hydroxyacetanilide, a slightly bitter, white, odorless, crystalline powder, is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:



$C_8H_9NO_2$ MW = 151.17

Each tablet contains:

Hydrocodone Bitartrate (Warning: May be habit forming)	10 mg
Acetaminophen	500 mg

In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, starch (corn), and stearic acid.

CLINICAL PHARMACOLOGY

Hydrocodone is a semisynthetic narcotic analgesic and antitussive with multiple actions qualitatively similar to those of codeine. Most of these involve the central nervous system and smooth muscle. The precise mechanism of action of hydrocodone and other opiates is not known, although it is believed to relate to the existence of opiate receptors in the central nervous system. In addition to analgesia, narcotics may produce drowsiness, changes in mood and mental clouding.

The analgesic action of acetaminophen involves peripheral influences, but the specific mechanism is as yet undetermined. Antipyretic activity is mediated through hypothalamic heat regulating centers. Acetaminophen inhibits prostaglandin synthetase. Therapeutic doses of acetaminophen have negligible effects on the cardiovascular or respiratory systems; however, toxic doses may cause circulatory failure and rapid, shallow breathing.

Pharmacokinetics: The behavior of the individual components is described below.

Hydrocodone: Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 ± 5.2 ng/mL. Maximum serum levels were achieved at 1.3 ± 0.3 hours and the half-life was determined to be 3.8 ± 0.3 hours.

COPY 2

Hydrocodone exhibits a complex pattern of metabolism including O-demethylation, N-demethylation and 8-keto reduction to the corresponding 6-α- and 6-β-hydroxymetabolites.

See OVERDOSAGE for toxicity information.

Acetaminophen: Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.

See OVERDOSAGE for toxicity information.

INDICATIONS AND USAGE

Hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain.

CONTRAINDICATIONS

This product should not be administered to patients who have previously exhibited hypersensitivity [illegible] ne or acetaminophen.

WARNINGS

Respiratory Depression: At high doses or in sensitive patients, hydrocodone may produce dose-related [illegible]piratory depression by acting directly on the brain stem respiratory center. Hydrocodone also affects the center that controls respiratory rhythm, and may produce irregular and periodic breathing.

Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a preexisting increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions: The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

PRECAUTIONS

General: Special Risk Patients: As with any narcotic analgesic agent, hydrocodone bitartrate and acetaminophen tablets should be used with caution in elderly or debilitated patients, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.

Cough Reflex: Hydrocodone sup[illegible]sses the cough r[illegible] as with all narcotics, caution should be exercised when hydrocodone bitartrate and acetaminophen tablets are used p[illegible]toperatively and in p[illegible]tients with pulmonary disease.

Information for Patients: Hydrocodone, like all narcotics, may impair mental [illegible] physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery; patients [illegible] be cautioned accordingly.

Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.

Hydrocodone may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

Laboratory Tests: In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.

Drug Interactions: Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone bitartrate and acetaminophen tablets may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced.

The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations m[illegible] effect of either the antidepressant or hydrocodone.

Drug/Laboratory Test Interactions: Acetaminophen may produce false-positive test [illegible] 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment of Fertility: No adequate studies ha[illegible] been conducted in animals to determine whether h[illegible] or [illegible]etaminophen have a potential for carcinogenesis, mutagenesis, or [illegible]pairment of fertility.

Pregnancy: *Teratogenic Effects:* Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Hydrocodone bitartrate and acetaminophen tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.

Labor and Delivery: As with all narcotics, administration of this product to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.

Nursing Mothers: Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

The most frequently reported adverse reactions are light-headedness, dizziness, sedation, nausea and vomiting. These effects seem to be more prominent in ambulatory than in non-ambula[illegible], and some of these adverse reactions may be alleviated if the patient lies down.

Other adverse reactions include:

Central Nervous System: Drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, psychic dependence, mood changes.

Gastrointestinal System: Prolonged administration of hydrocodone bitartrate and acetaminophen tablets may produce constipation.

Genitourinary System: Ureteral spasm, spasm of vesical sphincters and urinary retention have been reported with opiates.

Respiratory Depression: Hydrocodone bitartrate may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see OVERDOSAGE).

Dermatological: Skin rash, pruritus.

The following adverse drug events may be borne in mind as potential effects of acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.

Potential effects of high dosage are listed in the OVERDOSAGE section.

DRUG ABUSE AND DEPENDENCE

[illegible]ed Substance: Hydrocodone bitartrate and acetaminophen tablets are classified as a Schedule III controlle[illegible]ance.

[illegible] Dependence: Psychic dependence, physical dependence, and tolerance may develop upon repeated ar[illegible]ion of narcotics; [illegible] hydroco[illegible] this product should be prescribed and administered with caution. However, psychic dependence is [illegible] to develop when [illegible] bitartrate and acetaminophen tablets are used for a short time for the treatment of pain.

Physical [illegible]endence, the condition in which continued administration of the drug is required to prevent the appearan[illegible] withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued narcotic use, although some m[illegible] degree of physical dependence may develop after a few days of narcotic therapy. Tolerance, in which increasingly large doses are required in order to produce the same degree of analgesia, is manifested initially by a shortened duration of analgesic effect, and subsequently by decreases in the intensity of analgesia. The rate of development of tolerance varies among patients.

OVERDOSAGE

Following an acute overdosage, toxicity may result from hydrocodone or acetaminophen.

Signs and Symptoms:

Hydrocodone: Serious overdose with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis) extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdosage, anoxia, circulatory collapse, cardiac arrest and death may occur.

Acetaminophen: In acetaminophen overdosage: dose-dependent, potentially [illegible]atic necrosis is the most serious ad[illegible] effect [illegible]nal

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 040210

CHEMISTRY REVIEW(S)

1. CHEMISTRY REVIEW NO. 2

2. ANDA # 40-210

3. NAME AND ADDRESS OF APPLICANT
Peachtree Pharmaceuticals
1950 Lake Park Drive
Smyrna ,GA 30080

4. LEGAL BASIS FOR SUBMISSION
Certify to the best of their knowledge that any patent for the listed product or marketing exclusivity either has not been filed, or has expired prior to the filing of this application.

Listed Product: D. M. Graham - Lortab® 10/500, ANDA #40-100

5. SUPPLEMENT(s)
N/A

6. PROPRIETARY NAME
None

7. NONPROPRIETARY NAME
Hydrocodone Bitartrate and Acetaminophen

8. SUPPLEMENT(s) PROVIDE(s) FOR:
N/A

9. AMENDMENTS AND OTHER DATES:

Firm:
9/13/96 - Original.
10/28/96 - O/NC, regarding RLD.
11/15/96 - O/NC, regarding RLD.
4/4/97 - Response to 1st def. letter (chem.). Subject of this review.

FDA:
10/28/96 - Phone memo, change in ownership of RLD.
11/14/96 - Phone memo, regarding RLD.
11/20/96 - Acknowledgment.
1/9/97 - Bio. review, waiver granted.
1/15/97 - Bio. letter, acceptable at this time.
3/21/97 - 1st def. letter, facsimiles (chem.).

10. PHARMACOLOGICAL CATEGORY
Narcotic Analgesic

11. Rx or OTC
℞

12. RELATED IND/NDA/DMF(s)

(b)4 - Confidential Business

(b)4 - Confidential Business

13. DOSAGE FORM
Tablet

14. POTENCY
10 mg/500 mg

15. CHEMICAL NAME AND STRUCTURE

Acetaminophen USP
$C_8H_9NO_2$; M.W. = 151.16



4'-Hydroxyacetanilide. CAS [103-90-2]

Hydrocodone Bitartrate USP
$C_{18}H_{21}NO_3 . C_4H_6O_6 . 2\frac{1}{2}H_2O$; M.W. = 494.50



4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5). CAS [34195-34-1; 6190-38-1]

16. RECORDS AND REPORTS
N/A

17. COMMENTS
Method validation not needed, product is USP. DMFs, EER, labeling, and Bio. are satisfactory

18. CONCLUSIONS AND RECOMMENDATIONS
Approval

19. REVIEWER:
Norman Gregory

DATE COMPLETED:
4/11/97 (Chem.)
5/22/97 (Labeling)

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER 040210

BIOEQUIVALENCE REVIEW(S)

ANDA 40-210

Peachtree Pharmaceuticals
Attention: Lex Smith
1950 Lake Park Drive
Smyrna GA 30080

JAN 15 1997

Dear Sir:

Reference is made to your abbreviated new drug application submitted pursuant to Section 505 (j) of the Federal Food, Drug and Cosmetic Act for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 10/500 mg.

1. The Division of Bioequivalence has completed its review and has no further questions at this time.

2. The dissolution testing will need to be incorporated into your stability and quality control programs as specified in USP 23.

Please note that the bioequivalency comments expressed in this letter are preliminary. The above bioequivalency comments may be revised after review of the entire application, upon consideration of the chemistry, manufacturing and controls, microbiology, labeling or other scientific or regulatory issues. A revised determination may require additional information and/or studies, or may conclude that the proposed formulation is not approvable.

Sincerely yours,

/S/

Rabindra Patnaik, Ph.D.
Acting Director, Division of Bioequivalence
Office of Generic Drugs
Center for Drug Evaluation and Research

JAN - 9 1997

Hydrocodone Bitartrate/
Acetaminophen
10 mg/500 mg Tablets
ANDA #40-210
Reviewer: Moheb H. Makary
WP #40210W.996

Peachtree Pharmaceuticals
Smyrna, GA
Submission Date:
September 13, 1996

Review of a Dissolution Data and Waiver Request

I. Introduction:

Hydrocodone bitartrate is a phenanthrene-derivative opiate agonist that is used as an antitussive and analgesic agent. Acetaminophen is a synthetic non-opiate derivative of p-aminophenol which produce analgesia and antipyresis.

The combinations of Acetaminophen/Hydrocodone bitartrate are commercially available as 500 mg/5 mg capsule or 500 mg/2.5 mg, 500 mg/5 mg, 500 mg/7.5 mg, 500 mg/10 mg and 750 mg/7.5 mg tablets.

II. Objective:

The firm has requested a waiver of the *in vivo* bioequivalence requirements for its Hydrocodone Bitartrate 10 mg and Acetaminophen 500 mg Tablets USP. The firm conducted dissolution testing on its test product comparing it to Graham's Lortab[R] 500 mg/10 mg Tablet.

Acetaminophen/Hydrocodone Bitartrate Tablets are coded AA on various strengths in the Orange Book.

III. Dissolution Testing:

The following USP 23 conditions were used:

Apparatus:	2 (paddle) at 50 rpm
Medium:	900 mL phosphate buffer pH 5.8
Test product:	Peachtree's Hydrocodone Bitartrate/Acetaminophen 10 mg/500 mg Tablets, lot #EXPT9417

Reference product: Graham's Lortab[R] (Acetaminophen/Hydrocodone Bitartrate 500 mg/10 mg) Tablets, lot #WL1096122A

The dissolution testing results are shown in Table I.

IV. Formulation:

The formulation of the test product is shown below:

Component	mg/Tablet
Starch NF	(b)4 - Confidential
Microcrystalline Cellulose NF	(b)4 -
Hydrocodone Bitartrate USP	10.0
Acetaminophen USP	(b)4 -
Croscarmellose Sodium NF	
Colloidal Silicon Dioxide NF	
Stearic Acid NF	
	========
	799.96 mg

(b)4 - Confidential Business

V. Comment:

The dissolution testing results for the test product met the USP specifications.

VI. Recommendations:

1. The dissolution testing conducted by Peachtree Pharmaceuticals, on its Hydrocodone Bitartrate/Acetaminophen, 10 mg/500 Tablets, lot #EXPT9417, is acceptable. The waiver of the *in vivo* bioequivalence study requirements is granted for the test product Hydrocodone Bitartrate/Acetaminophen, 10 mg/500 Tablets based on 21 CFR 320.22 (c). The Division of Bioequivalence deems Hydrocodone Bitartrate/Acetaminophen, 10 mg/500 Tablets, manufactured by Peachtree Pharmaceuticals, to be bioequivalent to Lortab[R] 500 mg/10 mg Tablet, manufactured by Graham Laboratories, Inc.

2. The dissolution testing should be incorporated into the firm's manufacturing controls and stability program. The dissolution testing should be conducted in 900 mL of phosphate buffer pH 5.8, at 37 °C using USP 23 apparatus 2 (paddle) at 50 rpm.
The test product should meet the following specifications:

> Not less than (b)4 of the labeled amount of both acetaminophen and hydrocodone bitartrate in the dosage form are dissolved in 30 minutes.

The firm should be informed of the above recommendations.

/S/

Moheb H. Makary, Ph.D.
Division of Bioequivalence
Review Branch III

RD INITIALLED RMHATRE /S/
FT INITIALLED RMHATRE 1/7/97

Concur: /S/ Date: 1/9/97
Rabindra Patnaik, Ph.D.
Acting Director
Division of Bioequivalence

MMakary/1-7-97 wp 40210W.996
cc: ANDA #40-210, (original), HFD-658 (Makary), Drug File.

Table I. In Vitro Dissolution Testing

Drug (Generic Name):Hydrocodone Bitartrate/Acetaminophen Tablets
Dose Strength:10 mg/500 mg
ANDA No.:40-210
Firm:Peachtree Pharmaceuticals
Submission Date: September 13, 1996
File Name:40210W.996

I. Conditions for Dissolution Testing:

USP XXII Basket: Paddle: X RPM: 50
No. Units Tested: 12
Medium: 900 mL of phosphate buffer pH 5.8
Specifications:NLT (b)4 in 30 minutes for both products
Reference Drug: Lortab (Graham) 500 mg/10 mg Tablet
Assay Methodology (b)4 -

II. Results of In Vitro Dissolution Testing:Hydrocodone Bitartrate

Sampling Times (Minutes)	Test Product Lot #EXPT9417 Strength(mg) 10			Reference Product Lot #WL1096122A Strength(mg) 10		
	Mean %	Range	%CV	Mean %	Range	%CV
10	98.9	(b)4 - Confidential Business	1.5	100.5	(b)4 - Confidential Business	1.2
20	98.1		1.5	99.4		1.1
30	97.4		1.4	98.3		1.1
45	96.2		1.6	96.8		1.2

Acetaminophen

Sampling Times (Minutes)	Test Product Lot #EXPT9417 Strength(mg) 500			Reference Product Lot #WL1096122A Strength(mg) 500		
	Mean %	Range	%CV	Mean %	Range	%CV
10	94.8	(b)4 - Confidential Business	1.6	96.7	(b)4 - Confidential Business	1.0
20	94.7		2.0	96.0		1.2
30	94.3		1.9	95.1		1.2

45	93.6	(b)4 -	1.9	94.6	(b)4 -	1.4